Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel
NASDAQ:IPSC

Century Therapeutics Q2 2025 Earnings Report

Century Therapeutics logo
$2.41 +0.09 (+3.88%)
Closing price 06/29/2026 04:00 PM Eastern
Extended Trading
$2.44 +0.03 (+1.45%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Century Therapeutics EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.38
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Century Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.03 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Century Therapeutics Announcement Details

Quarter
Q2 2025
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Century Therapeutics' Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 10, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Century Therapeutics' Q2 2025 Press ReleasePress Release
(8-K)
Century Therapeutics' Q2 2025 Quarterly reportQuarterly report
(10-Q)

Century Therapeutics Earnings Headlines

Century Therapeutics (NASDAQ:IPSC) Cut to Sell at Wall Street Zen
June 27 at 1:24 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30863597
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation
June 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/heres-why-were-watching-century-133825514.html
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
 |  Chaikin Analytics (Ad)
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813
June 10, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/century-therapeutics-ipsc-reports-positive-preclinical-results-for-diabetes-cell-therapy-cnty-813-1779047/
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
June 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/08/3308455/0/en/new-cnty-813-preclinical-data-demonstrate-durable-glucose-control-immune-evasion-under-alloimmune-pressure-and-scalable-manufacturing-at-ada-2026.html
Mizuho initiates coverage of Century Therapeutics (IPSC) with outperform recommendation
May 28, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/mizuho-initiates-coverage-of-century-therapeutics-ipsc-with-outperform-recommendation/ar-AA24eOW2
See More Century Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email.

About Century Therapeutics

Century Therapeutics (NASDAQ:IPSC) is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates. Early-stage programs include iPSC-derived NK cell candidates engineered for enhanced tumor targeting and persistence, alongside T cell programs incorporating novel receptor constructs. Century has established strategic collaborations with leading pharmaceutical partners to advance preclinical research and prepare select programs for clinical evaluation.

Founded in 2019 as a spin-out from the Wistar Institute and the University of Pennsylvania, Century Therapeutics is headquartered in Philadelphia. Since its inception, the company has built multidisciplinary teams across research, manufacturing and regulatory affairs. Century’s leadership brings experience from established biopharmaceutical companies and academic institutions, supporting its goal of delivering transformative cell therapies to patients worldwide.

View Century Therapeutics Profile
Earnings Tools